Alpharma acquires UDL products

Published: 28-May-2001


Alpharma's US pharmaceutical division has acquired eight approved ANDAs for six liquid bottled and seven unit dose products from UDL Laboratories of Largo, FL, US, a part of Mylan Labs. It has also acquired five pipeline products, including one with tentative approval. The acquired products have annual sales of around US$12m.

See more

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Read more
Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Ardena strengthens leadership team with new quality and information officers Appointments reinforce focus on quality, compliance, and digital integration across global operations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing sustainable change through labelling choice Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
  5. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Hi Tech Manufacturing

Haier Biomedical sets a new benchmark for smart, secure LN2 storage

Haier Biomedical has introduced its next-generation CryoBio LN2 storage systems, developed with input from biobanks, research institutes and hospitals handling large-scale sample collections across the UK
Regulatory

Poolbeg Pharma granted European patent for flu drug

POLB 001 targets the body's inflammation machinery and prevents dangerous immune overreactions. The drug could also be used in the treatment of other inflammation-based diseases, such as Cytokine Release Syndrome
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
You need to be a subscriber to read this article.
Click here to find out more.
Pharma 5.0

AI takes the lead: how computational discovery is redefining drug R&D

AI-native modelling and GPU-driven simulation are transforming drug discovery workflows and reshaping the balance between pharma and biotech
Subscribe now